Success Metrics

Completion Rate
0%(0/2)
Active Trials
2(50%)
Terminated
2(50%)

Phase Distribution

Ph phase_2
1
25%
Ph phase_1
2
50%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Terminated(2)

Detailed Status

Terminated2
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (66.7%)
Phase 21 (33.3%)

Trials by Status

terminated250%
recruiting250%

Recent Activity

2 active trials
Showing 4 of 4
terminatedphase_1

A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene

NCT05497453
recruitingphase_2

A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors

NCT04673942
terminatedphase_1

A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors

NCT05716295
recruiting

The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors

NCT05037825

Clinical Trials (4)

Showing 4 of 4 trials
NCT05497453Phase 1

A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene

Terminated
NCT04673942Phase 2

A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors

Recruiting
NCT05716295Phase 1

A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors

Terminated
NCT05037825

The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors

Recruiting

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4